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Primary tumours of the gastrointestinal tract usually can be
removed efficiently by surgery, but 50–60% of all patients develop
metastases within the next 5 years, mostly in the liver (Vahrmeijer
et al, 1995; Kemeny, 1996). Hepatic metastases are difficult to
treat with current treatment regimens. Chemotherapy using fluoro-
pyrimidines, often in combination with modulators like leuco-
vorin, methotrexate or interferon, is most often used in these
patients, but with a minimal increase in survival rates (Meropol
et al, 1995). Hepatic arterial infusion of chemotherapeutics results
in higher response rates and survival in preclinical and clinical
studies (Marinelli et al, 1991; Kemeny, 1995), indicating that local
drug application may offer good prospects.
5-Fluoro-2¢-deoxyuridine (FUdR), a cytotoxic drug of the group
of fluoropyrimidines, and its metabolite 5-fluorouridine (5-FU)
are among the most often used cytotoxic drugs in the treatment of
disseminated colorectal cancer. FUdR needs to be converted to
FdUMP (5-fluoro-2¢-deoxyuridine-5¢-monophosphate) which is a
potent inhibitor of thymidylate synthase, responsible for the gener-
ation of dTMP (2¢-deoxy-thymidine-5¢-monophosphate). The
resulting lack of dTMP leads to inhibition of DNA-synthesis
(Danenberg, 1977). FdUMP can be converted to FdUTP (FUdR-
5¢-triphosphate) which can be incorporated into DNA. FUdR can
also be converted to 5-FU which is metabolized into FUTP
(5-fluorouridine-5¢-triphosphate), a substrate for RNA polymerase
and is incorporated into RNA. Incorporation of FdUTP or FUTP
into DNA or RNA, respectively, causes damage to these nucleic
acids (Myers, 1981).
Liposomes have been shown to be potentially attractive carriers
for anticancer drugs (Gregoriadis, 1995; Allen, 1997; Storm et al,
1997) because they prevent the drug from degradation in circula-
tion and may diminish toxic side-effects by altering pharma-
cokinetic behaviour. Besides, it has been shown that liposomes,
and consequently the liposomal drug, may accumulate in tumour
areas provided that the liposomes are small and have a sufficiently
long circulation time (Papahadjopoulos et al, 1991; Vaage et al,
1997). The latter can be achieved for example by the ganglioside
GM1 or polyethyleneglycol (PEG) (Allen et al, 1987, 1991). A
further increase in tumour localization of liposomes may be
achieved by the coupling of a tumour cell-specific monoclonal
antibody to the liposomes (immunoliposome), to allow specific
interaction with the tumour cells (Martin et al, 1982; Maruyama
et al, 1990; Ahmad et al, 1993).
In this study we investigated the possibility of using liposomes
to deliver FUdR into rat CC531 colon adenocarcinoma cells. A
liver metastases model of this tumour has been developed, offering
a representative model for liver metastases of colon cancer in
humans (Marquet et al, 1984; Thomas et al, 1993; Dingemans
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et al, 1994). The monoclonal antibody, CC52, specific for a
surface antigen on CC531 tumour cells (Beun et al, 1992, 1993),
was used as a specific targeting device.
Since FUdR is not efficiently retained in liposomes under in
vivo conditions we synthesized a lipophilic dipalmitoyl ester of
FUdR, FUdR-dP (Nishizawa et al, 1965), to anchor the drug in the
liposomal bilayer (Schwendener et al, 1985; Van Borssum
Waalkes et al, 1993). We showed that FUdR-dP remains firmly
associated with the liposomes and does not exchange with serum
components such as albumin or lipoproteins or with liposomal
bilayers (Van Borssum Waalkes et al, 1993).
FUdR-dP was incorporated in several types of (immuno)lipo-
somes varying in size and composition. All formulations were
tested for their antiproliferative activity towards CC531 colon
cancer cells in vitro. To study the interaction of the liposomes with
CC531 cells and the possible mechanism of delivery of the drug to
the cells, we assessed association, internalization and degradation
of the liposomes and of the lipophilic prodrug.
MATERIALS AND METHODS
Materials
FUdR,  N-succinimidyl-S-acetylthioacetate (SATA) and choles-
terol (Chol) were obtained from Sigma (St Louis, MO, USA). Egg
yolk phosphatidylcholine (PC), maleimido-4-(p-phenylbutyryl)-
phosphatidylethanolamine (MPB-PE) and methoxypoly(ethyl-
eneglycol)2000-distearoylphosphatidylethanolamine (PEG2000-DSPE)
were purchased from Avanti Polar Lipids (Alabaster, AL, USA).
Bovine brain ganglioside GM1 was obtained from Calbiochem
(La Jolla, CA, USA) cholesteryl-[14C]-oleate, [3H]-cholesterylo-
leylether and [methyl-3H]-thymidine were obtained from
Amersham (Buckinghamshire, UK), 5-[6-3H]-fluoro-2¢-deoxyuri-
dine (3H-FUdR) was obtained from DuPont NEN (Wilmington,
DE, USA). All other chemicals were analytical grade or the best
grade available. Polycarbonate filters for liposome extrusion using
a high-pressure extruder were from Costar (Cambridge, MA,
USA). Filters for liposome extrusion using the Liposofast Basic
extruder were from Avestin Inc. (Ottawa, ON, Canada).
Monoclonal antibody
The monoclonal antibody CC52 (IgG1), recognizing a surface
antigen on CC531 colon adenocarcinoma cells, was developed in
the department of Pathology, Leiden University Medical Center,
The Netherlands (Beun et al, 1992). A murine IgG1 monoclonal
antibody against human B-cells used as an irrelevant control anti-
body, was a gift from Dr C Thomas, Department of Physiological
Chemistry, Groningen. Both antibodies were purified from culture
supernatant by protein A-sepharose (Pharmacia, Woerden, The
Netherlands) chromatography, according to the manufacturer’s
instructions.
Synthesis of FUdR-dP
FUdR-dP was synthesized as described earlier (Van Borssum
Waalkes et al, 1993). Briefly, 0.4 mmol of FUdR was dissolved in
1 ml of dimethylacetamide to which 0.8 mmol of palmitoylchlo-
ride was added. For the synthesis of 3H-FUdR-dP, 25 mCi of 3H-
FUdR, labelled in the uracil moiety, was added per mmol of FUdR.
The mixture was incubated overnight under constant shaking at
40°C. To the mixture distilled water was added, the resulting white
precipitate was applied to a glass filter and washed with distilled
water. FUdR-dP was recrystallized three times from methanol.
Purity of the compound was checked by thin-layer chroma-
tography.
Liposomes
Liposomes were composed of PC and 30 or 40 mol% Chol.
Liposomes to which CC52 antibodies were coupled contained
0.025 mol MPB-PE per mol lipid (cholesterol and phospholipid).
Long-circulating liposomes were prepared by incorporating 0.06
mol GM1 or 0.04 mol PEG2000-DSPE per mol lipid. FUdR-dP and
3H-FUdR-dP (specific activity 25 mCi mmol–1) was incorporated
in the liposomes at a level of 2 or 3 mol %. When required, lipo-
somes were labelled with trace amounts of [3H]-cholesteryl-
oleylether (1 Ci mol–1 lipid) and cholesteryl-[14C]-oleate (0.4 Ci
mol–1 lipid). Lipids dissolved in chloroform:methanol (9:1), were
mixed and dried under nitrogen pressure, dissolved in cyclohexane
and lyophilized. Lipids were hydrated in HN-buffer (10 mM N-2-
hydroxyethylpiperazine-N’-2-ethanesulphonic acid (HEPES), 135
mM sodium chloride), pH 7.4 or, for coupling of antibodies in
HN-buffer, pH 6.7. Liposomes were sized by repeated extrusion
through filters with a pore size of 200 or 50 nm using a high-pres-
sure extruder (Lipex, Vancouver, Canada) or a LiposoFast Basic
(Avestin Inc. Ottawa, Canada). Phospholipid phosphorus of each
liposome preparation was determined by a phosphate assay after
perchloric acid destruction (Böttcher et al, 1961). Total liposomal
lipid concentrations were calculated, taking into account the
amount of cholesterol in the liposome preparations. Particle size
and size distribution were determined by dynamic laser light scat-
tering with a Nicomp model 370 submicron particle analyser
(Nicomp, Santa Barbara, CA, USA), using the volume distribution
curves for obtaining the diameter of the liposomes. Liposomes
extruded through 200 nm had a diameter of 179 nm ± 61 nm
(mean ± standard deviation (s.d.)) and are referred to as 200-nm
liposomes; liposomes extruded through 50 nm had a diameter of
82 nm ± 25 nm and are referred to as 50-nm liposomes.
Coupling of antibodies to liposomes
Monoclonal antibodies were coupled to MPB-PE containing lipo-
somes by a sulphhydryl-maleimide coupling method as described
previously (Derksen et al, 1985). Briefly, free sulfhydryl groups
were introduced in the antibody, using the heterobifunctional
reagent SATA. Free SATA was separated from the derivatized anti-
body by gel permeation chromatography using Sephadex G-50.
Antibody with reactive sulfhydryl groups, induced by deacety-
lating the ATA-protein, were incubated with MPB-containing lipo-
somes for 4 h at room temperature at a ratio of 0.3 mg antibody per
mmol of lipid. N-ethylmaleimide (8 mM in HN-buffer, pH 7.4) was
added to cap unreacted sulfhydryl groups. Unconjugated antibody
was separated from liposomes by flotation on a metrizamide
gradient as described before (Kamps et al, 1996). Hereafter,
immunoliposomes were extensively dialysed against HN-buffer,
pH 7.4 and characterized by determining protein content using IgG
as a standard (Petterson, 1977), phospholipid phosphorus content
and particle size. PC/Chol-immunoliposomes contained 67–69 mg,
PC/Chol-GM1-immunoliposomes 52–71 mg and PC/Chol-PEG-
immunoliposomes 17–38 mg CC52 per mmol of liposomal lipid.
PC/Chol-PEG-liposomes contained 92 mg  mmol–1 of irrelevant1720 GA Koning et al
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murine IgG1. Liposomes increased in size as a result of the
coupling of CC52; 200-nm liposomes increased by 15%, 50-nm
PC/CH-liposomes by 80%, 50-nm GM1-liposomes by 39% and
CC52-PC/Chol/PEG-liposomes by 7%, no aggregates were
observed. Liposomes were stored at 4°C under nitrogen and used
within 2 weeks after preparation.
Cell culture
CC531 colon adenocarcinoma is a 1,2-dimethylhydrazine-induced
carcinoma of the colon of WAG/Rij-rats (Marquet et al, 1984).
Cells were maintained in 75-cm2 culture flasks (Costar,
Cambridge, MA, USA) in RPMI-1640 medium with 25 mM
HEPES (Gibco BRL, Breda, The Netherlands) supplemented with
10% heat-inactivated fetal calf serum (FCS) (Gibco), fresh
L-glutamine (2 mM) and penicillin–streptomycin (100 U ml–1 and
100 mg ml–1 respectively) (Gibco) at 37°C in a humidified atmos-
phere consisting of 5% carbon dioxide in air. Cells were sub-
cultured at 80% confluency.
In vitro proliferation assay
After trypsinization, CC531 cells were plated in 96-well plates
(Costar) in culture medium, at a density which allows cells to be in
the log-phase of growth during determination of the proliferation;
2000 cells per well for 72-h treatment and 3500 cells per well for
48-h treatment. Cells were allowed to adhere overnight, whereafter
varying amounts of the different test compounds were added. In
incubations with liposomes not containing FUdR-dP, the same
amounts of liposomal lipid were added as for FUdR-dP containing
liposomes. Twenty hours before terminating the incubations, 0.06
mCi of [methyl-3H]-thymidine (specific activity 5 Ci mmol–1) was
added per well. At the end of the incubations, cells were washed
twice with phosphate-buffered saline (PBS) (137.9 mM sodium
chloride, 2.7 mM potassium chloride, 8.1 mM sodium phosphate
and 1.5 mM KH2PO4, pH 7.4) and lysed in sample buffer (0.125 M
tri-sodium-citrate, 4% sodium dodecyl sulphate (SDS), 0.1 M
b-mercaptoethanol and 0.2 M glycerol). Samples were harvested
for liquid scintillation counting with Ultima Gold XR (Packard
Instruments, Groningen, The Netherlands). Proliferation was
expressed as the percentage 3H-thymidine incorporation of the
treated cells compared with untreated cells. The drug concentra-
tion causing 50% growth inhibition (IC50) was calculated by inter-
polation of the two values closest to 50% inhibition on the growth
inhibition curve.
Interaction of (immuno)liposomes and incorporated 3H-
FUdR-dP with CC531 cells
After trypsinization CC531 cells were plated on 6- or 24-well
plates (Costar) and left to grow for 2 days. One hour before the
start of the experiment cells were washed with PBS and fresh
medium with or without 10% FCS was added to the cells. For
determining association of liposomes, CC531 cells were incubated
in 24-well plates for 3 h in the absence of FCS with 200 nmol ml–1
tumour cell-specific immunoliposomes (CC52-PC/Chol/PEG-
liposomes), control liposomes without antibody (PEG-liposomes)
or liposomes with irrelevant murine IgG1 coupled (IgG1-
PC/Chol/PEG-liposomes), all labelled with 3H-COE.
Subsequently, medium was removed, cells were thoroughly
washed with ice-cold PBS and lysed using 0.4 M sodium
hydroxide. Cell-associated radioactivity was determined and
normalized for the amount of cellular protein as determined by
protein assay (Lowry et al, 1951) using BSA (bovine serum
albumin) as a standard. For determining liposome uptake and
degradation, cells were incubated in 6-well plates for 4, 8, 24 or 48
h with 100 nmol CC52-PC/Chol-liposomes double-labelled with
3H-cholesteryloleylether (3H-COE), a non-degradable marker and
cholesteryl-[14C]-oleate (14C-COA), an intracellularly degradable
marker which results in release of 14C-oleic acid from the cells as
described before (Derksen et al, 1988). Incubations were stopped
by removing the liposome-containing medium followed by thor-
ough washing of the cells with ice-cold PBS. Cells were harvested
by trypsinization and centrifugation. Cell-associated labels were
determined by combining the radioactivity in the supernatant and
in the cell pellet after lysing the cells with SDS and were normal-
ized for the amount of cellular protein as determined by protein
assay. The 3H:14C ratio of the cell-associated radioactivity was
calculated and taken as a measure of the degradation of the 14C-
COA and thus of liposome degradation.
For determining the uptake of immunoliposome-incorporated
3H-FUdR-dP, CC531 cells were incubated in the absence of FCS in
6-well plates for 3 h with 100 nmol 3H-FUdR-dP containing
CC52-MPB-liposomes, followed by a liposome-free incubation
period of 6 h. Radioactivity was measured in the medium, in the
supernatant after trypsin treatment with 0.05% trypsin for 10 min
and centrifugation (cell-bound label), and in the trypsin-treated
cell pellet (intracellular label) after lysing the cells with 10% SDS.
To discriminate between hydrophobic FUdR-dP and hydrophilic
FUdR or metabolites (hydrolysed prodrug), chloroform:methanol
extractions were performed by mixing sample, methanol, chloro-
form and PBS in a ratio of 4:10:9:5 (vol/vol). The chloroform and
methanol:water layers were isolated and 3H-label was measured by
liquid scintillation counting and normalized for the amount of
cellular protein.
Statistical evaluation
Statistical significance of differences was evaluated by a two-
tailed unpaired Student’s t-test.
RESULTS
Increased anti-tumour activity of FUdR-dP in
immunoliposomes
In Figure 1 the antiproliferative effects on CC531 cells of a 72-h
treatment with FUdR-dP incorporated in 200-nm GM1-containing
immunoliposomes are compared with those of 200-nm GM1-lipo-
somes without antibody and free FUdR. Liposomes not containing
FUdR-dP had no effect on tumour cell proliferation (not shown).
FUdR-dP in 200-nm CC52-GM1-liposomes was much more effec-
tive in inhibiting tumour cell proliferation than FUdR-dP in GM1-
liposomes without the CC52 antibody.
In Table 1 the FUdR-concentrations resulting in a 50% inhibi-
tion of tumour cell proliferation (IC50) are given to enable direct
comparison of the effect of various liposomal formulations and
treatment conditions on tumour cell toxicity. In case of immunoli-
posomal FUdR-dP the 50% inhibition of proliferation was reached
at a 13-fold lower drug-concentration than with FUdR-dP in lipo-
somes without antibody. At FUdR-concentrations of 10–6 M and
higher, FUdR-dP-containing immunoliposomes were able toImmunoliposomes against colon cancer 1721
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inhibit tumour cell growth almost completely, in contrast to FUdR-
dP in GM1-liposomes without CC52, which caused a maximum
inhibition of 60%, while free FUdR inhibited cell growth maxi-
mally by 85%. At the lower concentration range free FUdR was
more effective in inhibiting CC531 proliferation.
Antiproliferative activity of FUdR-dP in 50-nm
immunoliposomes
In vivo, target site accessibility will be favourably influenced by
decreasing liposome size and increasing circulation time by incor-
porating substances like GM1 or PEG.
Antiproliferative effects of FUdR-dP in 50-nm CC52-liposomes
are shown in Figure 2. At FUdR-concentrations of 10–7 M and
higher, FUdR-dP incorporated in 50-nm CC52-liposomes inhib-
ited tumour cell growth to the same extent as free FUdR, whereas
at lower concentrations free FUdR is more effective than immuno-
liposomal FUdR-dP. CC52-liposomes without FUdR-dP had only
minor effects on CC531 proliferation. Up to FUdR-concentrations
of 10–7 M no significant difference in antiproliferative potency was
observed between FUdR-dP containing 50-nm (Figure 2) or 200-
nm (Figure 1) CC52-GM1-liposomes. Both liposome preparations
showed comparable IC50-values (Table 1). However, a notable
difference between the smaller and the larger liposomes in the
extent of growth inhibition was observed at concentrations higher
than 10–7 M. With the 50-nm CC52-liposomes a proliferation inhi-
bition of maximally 80% was attained, in contrast to the 100% for
the 200-nm CC52-liposomes.
Table 1 IC50 values of inhibition of CC531 colon cancer cell proliferation by liposomal FUdR-dP formulations and FUdR
Liposome composition Chol Size Treatment IC50 IC50
(mol%) (nm) (h) FUdR FUdR
(M) (ng ml–1)
PC/Chol/FUdR-dP 30 200 72 3.1´10–7 77
PC/Chol/GM1/FUdR-dP 30 200 72 6.9´10–7 170
CC52-PC/Chol/GM1/FUdR-dP 30 200 72 5.5´10–8 13
CC52-PC/Chol/FUdR-dP 30 50 72 1.2´10–8 3
CC52-PC/Chol/GM1/FUdR-dP 30 50 72 3.4´10–8 8
CC52-PC/Chol/GM1/FUdR-dP 40 50 48 1.2´10–5 2954
CC52-PC/Chol/PEG/FUdR-dP 40 50 48 1.1´10–5 2708
CC52-PC/Chol/GM1/FUdR-dP 40 50 72 2.2´10–8 5
CC52-PC/Chol/PEG/FUdR-dP 40 50 72 1.0´10–7 24
Free FUdR 72 2.1´10–9 1
CC52-PC/Chol/GM1/FUdR-dP 40 50 24 + 48a 3.7´10–8 9
CC52-PC/Chol/PEG/FUdR-dP 40 50 24 + 48a 5.0´10–6 1234
Free FUdR 24 + 48a 8.6´10–7 213
aCells were treated for 24 h, followed by 48 h incubation in medium without liposomal or free drug.
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Figure 1 Proliferation of CC531 tumour cells as a function of the amount of
FUdR added as FUdR-dP in 200-nm liposomes or free FUdR. Proliferation
was assayed by 3H-thymidine incorporation and expressed as percentage of
label incorporated in untreated cells (± s.e.m.). Cells were incubated for 72 h
with: PC/Chol/GM1/FUdR-dP liposomes (u) (n = 6), CC52-
PC/Chol/GM1/FUdR-dP-liposomes (•) (n = 6) or free FUdR (n n) (n ³ 12)
Figure 2 Proliferation of CC531 tumour cells as a function of the amount of
FUdR added as FUdR-dP in 50-nm liposomes (30 mol % Chol) or free FUdR.
Cells were incubated for 72 h with CC52-liposomes composed of: PC/Chol
(D), PC/Chol/GM1 (l l), PC/Chol/FUdR-dP (s) or PC/Chol/GM1/FUdR-dP (•)
(all n = 6) or with free FUdR (n n) (n ³ 12). Proliferation is expressed as
percentage of the proliferation of untreated cells (average ± s.e.m.)1722 GA Koning et al
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FUdR-dP in long circulating immunoliposomes
Figure 3 compares the effect of 48- or 72-h treatment with FUdR-
dP in 50-nm CC52-GM1- or PEG-liposomes. Treatment for 24 h
did not result in a significant effect on proliferation. Treatment for
48 h (Figure 3A) with FUdR-dP-containing GM1-immunolipo-
somes or PEG-immunoliposomes caused a slightly but signifi-
cantly (P < 0.005) stronger inhibition of proliferation than free
FUdR at concentrations higher than 10–6 M.
Treatment for 72 h with FUdR-dP in CC52-GM1-liposomes
resulted in a slightly stronger inhibition of tumour cell growth than
FUdR-dP in CC52-PEG-liposomes (Figure 3B). At concentrations
lower than 10–7 M, free FUdR was the most effective. No effect of
cholesterol content in CC52-GM1-liposomes was observed
(Figures 2 and 3 and Table 1).
Treatment (24 h) with FUdR-dP immunoliposomes
In the experiments described thus far, the drug was left in contact
with the cells for the full 48-h or 72-h incubation period. In the
following experiment we incubated the cells for 24 h with the drug
formulation, then removed the medium containing the drug and
continued incubation for another 48 h in fresh drug-free medium.
FUdR-dP in CC52-GM1-liposomes at concentrations of 10–7 M
or lower, was more effective than FUdR-dP in CC52-PEG-
liposomes and even slightly more effective than the free drug
(P < 0.05) (Figure 4 and Table 1). FUdR-dP in liposomes without
antibody had only minor effects on cell proliferation. Treatment
for 24 h with FUdR-dP in CC52-GM1-liposomes at concentrations
of 10–7 M and lower, followed by a drug-free incubation period of
48 h, resulted in antiproliferative effects comparable to those
obtained following a continuous treatment for 72 h (Figure 3B and
Table 1). A 24-h treatment with FUdR-dP in CC52-PEG-lipo-
somes resulted in lower levels of CC531 growth inhibition than a
72-h continuous treatment.
Mechanism of interaction of immunoliposomes with
CC531 cells and intracellular delivery of FUdR-dP
In the experiment presented in Table 2 association of different
radiolabelled liposome formulations with CC531 cells was deter-
mined. We compared the CC52-liposomes with liposomes
containing irrelevant IgG1 and liposomes without antibody. The
latter two showed levels of association of only about 10% of that
of tumour cell-specific CC52-liposomes demonstrating the speci-
ficity of interaction of the CC52-liposomes with CC531 cells.
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Figure 3 Effects of different treatment times with 50-nm CC52-PC/Chol-liposomes (40 mol % Chol) without or with FUdR-dP containing GM1 or PEG on the
proliferation of CC531 cells. Proliferation is expressed as percentage of the proliferation of untreated cells (average ± s.d.). PEG, no FUdR-dP (=); GM1, no
FUdR-dP (l l); PEG, FUdR-dP (t); GM1, FUdR-dP (•) (all n = 3) and free FUdR (n n) (n ³ 6). (A) A 48-h treatment. Only results of FUdR-dP containing
liposomes are shown, liposomes without the drug had no effect on the proliferation. (B) A 72-h treatment
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Figure 4 Antiproliferative effect of liposomal formulations of FUdR-dP;
effect of 24-h pre-treatment with 50-nm liposomes followed by 48-h
incubation without the drug on the proliferation of CC531 cells. Proliferation
is displayed as a percentage of the proliferation of untreated cells (average ±
s.d.). FUdR-dP-GM1-liposomes without CC52 (l l); CC52-FUdR-dP-PEG-
liposomes (t); CC52-FUdR-dP-GM1-liposomes (•) (all n = 3) and free FUdR
(n n) (n = 5)Immunoliposomes against colon cancer 1723
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To gain insight in the mechanism of interaction of the immuno-
liposomes with the tumour cells and the way the drug becomes
available inside the cells we incubated the cells with double-
labelled immunoliposomes containing both the metabolically
degradable ester cholesteryl-[14C-]oleate and the non-metaboliz-
able analogue 3H-cholesteryloleylether. Following an endocytic
uptake process the cholesterylester will be hydrolysed intralysoso-
mally and 14C-oleate will be released from the cells. Internalized
cholesterylether, on the other hand, will remain cell-associated and
thus the cellular 3H:14C ratio is expected to increase when the
uptake mechanism involves an endocytic process (Derksen et al,
1988). During a 48-h incubation, the cellular 3H:14C ratio remains
essentially constant irrespective of the presence or absence of
serum in the medium, indicating that the cholesterylester is not
exposed to a lysosomal environment intracellularly (Figure 5).
Also the fate of the prodrug in the cells was followed by
incubating cells for 3 h with CC52-MPB-liposomes containing
3H-FUdR-dP followed by a 6-h incubation period without
immunoliposomes. Within 3 h, 1.25 ± 0.09 mmol FUdR-dP mg–1
cell protein (average of six determinations ± s.e.m.) was associated
with the tumour cells. Six hours after ending the incubation with
liposomes, the medium contained 0.46 ± 0.05 mmol of FUdR(-dP)
mg–1 cell protein of which 84 ± 7% was water soluble, repre-
senting hydrolysed prodrug. The amount of cell-bound liposomal
FUdR-dP was 0.62 ± 0.04 mmol mg–1 cell protein, whereas 0.17 ±
0.03 mmol FUdR(-dP) mg–1 cell protein was retrieved intracellu-
larly of which 49 ± 11% was water soluble FUdR. These results
demonstrate that, in sharp contrast to the immunoliposome-incor-
porated cholesterylester, immunoliposomal FUdR-dP is rapidly
hydrolysed by CC531 cells, resulting in efficient intracellular
delivery of active drug.
DISCUSSION
The establishment of a tight interaction between liposomes and
tumour cells, by means of antibody–antigen interactions, resulted
in a major increase in the antiproliferative efficacy and thus,
apparently, of the delivery of FUdR-dP to CC531 cells as
compared to liposomes without specific antibody. The specificity
of the interaction of CC52-liposomes with CC531 cells was
confirmed by a tenfold higher level of association of CC52-
liposomes compared to liposomes carrying irrelevant IgG or
liposomes without antibody.
In order to become effective, liposomal FUdR-dP has to be
hydrolysed to the active parent compound FUdR. Van Borssum
Waalkes et al (1993) showed that little or no hydrolysis of
FUdR-dP occurs in serum. Extensive hydrolysis of FUdR-dP,
leading to the virtually complete availability of the active drug in
48 to 72 h, can only occur after uptake of the prodrug and subse-
quent intracellular hydrolytic removal of the esterified palmitic
acid chains (Van Borssum Waalkes et al, 1990). The higher
antiproliferative activity towards CC531 colon cancer cells of free
FUdR as compared to FUdR-dP in liposomes without antibody
(Figure 1) indicates that only a small part of the liposomal prodrug
from these liposomes is hydrolysed into FUdR. The increase in
antiproliferative activity obtained by coupling a tumour cell-
specific antibody to the FUdR-dP-containing liposomes indicates
the involvement of a different mechanism in the release of active
drug from the immunoliposomes.
Endocytic uptake of the immunoliposomes is unlikely to play a
role in the entrance of FUdR-dP into the tumour cells. For example,
the similar effectiveness of the 50-nm and the 200-nm immunolipo-
somes argues against such a mechanism because particles > 120 nm
are generally not endocytosed by non-phagocytic cells (Scherphof,
1991). Furthermore, Figure 5 shows that liposomal cholesteryloleate
is not hydrolysed by the tumour cells within a timespan of as long as
48 h, this also argues against endocytic uptake of the CC52-lipo-
somes. Nonetheless, the tight interaction of the immunoliposomes
with the tumour cells leads to efficient intracellular delivery of
FUdR as was confirmed by tracing 3H-FUdR-dP and its deacylated
metabolites during the interaction of CC52-liposomes with CC531
cells. Considerable amounts of FUdR-dP and hydrolysed prodrug
were detected intracellularly, suggesting the involvement of an
intracellular hydrolytic process in the release of active FUdR. We
postulate a selective transfer of FUdR-dP from the immunolipo-
somal bilayer to the plasma membrane, followed by tumour cell
mediated hydrolysis, yielding effective concentrations of active
drug intracellularly.
A transfer of FUdR-dP from the bilayer of immunoliposomes to
plasma membranes has been proposed before by us in collabora-
tion with Dr Leaf Huang, University of Pittsburgh, USA. FUdR-
dP incorporated in GM1-immunoliposomes targeted to lung
endothelium resulted in increased antitumour activity towards
lung metastases of EMT6 mouse mammary carcinoma as
Table 2 Association of tumour cell-specific liposomes and control
liposomes, with irrelevant murine IgG1 or without antibody coupled, with
CC531 colon cancer cells
Liposome Association with CC531 cells
(nmol lipid per mg cell protein) (± s.d.)
CC52-MPB-PEG 9.67 ± 1.61
IgG1-MPB-PEG 1.18 ± 0.28
MPB-PEG 1.00 ± 0.17
CC531 cells were incubated for 3 h with 3H-COE labelled liposomes
(200 nmol ml–1). Association is expressed as nmol liposomal lipid and
normalized for the amount of cellular protein.
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Figure 5 Lack of immunoliposome degradation by CC531 tumour cells.
Ratio 3H:14C associated with CC531 cells after incubation with CC52-
PC/Chol-liposomes double labelled with the non-degradable marker 3H-COE
and the intracellular degradable marker 14C-COA, followed in time.
Incubations without fetal calf serum (FCS) (l l) and with FCS (n n)
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compared to non-targeted liposomes. We tentatively ascribed this
to a transfer of FUdR-dP from the immunoliposomes to the plasma
membrane of the lung endothelial cells (Mori et al, 1995). Since
GM1 was previously shown to facilitate selective transfer of lipo-
somal bilayer constituents from liposomes to hepatocytes
(Hoekstra et al, 1980), this compound was hypothesized to facili-
tate transfer of FUdR-dP from liposomes to plasma membranes
(Scherphof et al, 1992). However, in our experiments, the presence
of GM1 in plain liposomes or in immunoliposomes did not enhance
the antiproliferative effect of FUdR-dP towards CC531 cells
compared to (immuno)liposomes without GM1 and thus, appar-
ently, GM1 did not augment the transfer of the prodrug to the
tumour cells. The FUdR-dP transfer to endothelial cells, as
mentioned above, may have been induced by the antibody–antigen
mediated interaction between the liposomal bilayer and the plasma
membrane, comparable to the transfer-mechanism postulated in
this paper. Cellular uptake of a liposome-associated lipophilic
derivative of methotrexate has been reported suggesting a similar
mechanism of drug uptake independent on internalization of the
entire liposome (Kinsky et al, 1987).
The somewhat stronger antitumour activity of 200-nm immuno-
liposomes as compared to the 50-nm vesicles, which was observed
at FUdR-dP concentrations of 10–6 M and higher, may be explained
by the larger number of FUdR-dP molecules incorporated per
vesicle in the larger liposomes. Also, more antibody-molecules are
coupled per vesicle, allowing a tighter interaction with the tumour
cells. For in vivo targeting to tumours, liposomes of 100 nm or
smaller are preferable to larger ones because of their longer circu-
lation time (Mayer et al, 1989) and a concomitantly higher chance
of extravasation in tumour areas (Papahadjopoulos et al, 1991).
The difference in antiproliferative efficacy between PEG-immuno-
liposomes and GM1-immunoliposomes in our experiments can be
ascribed to the three-fold higher amount of antibody coupled to the
latter ones. Although immunoliposomes containing GM1 show a
higher anti-tumour activity, it may be more advantageous, in vivo,
to apply PEG since rat and human serum contain anti-GM1-
antibodies which enhance rapid clearance of GM1-liposomes
(Liu et al, 1995).
The experiments, in which the anti-tumour effect was measured
48 h after a 24-h treatment with FUdR-dP in CC52-liposomes,
illustrate the potential advantage of immunoliposomes over non-
targeted liposomal FUdR-dP and free FUdR. This experimental
condition is considered to resemble more closely the in vivo
situation than the 72-h continuous treatment. By incorporating
FUdR-dP in (immuno)liposomes the circulation half-life of the
drug is drastically increased as compared to that of free FUdR,
which has a circulation half-life of only a few minutes (Ensminger
et al, 1978), and besides, immunoliposomes are expected to selec-
tively bind to the tumour cells. Both conditions will result in
increased duration of exposure of the tumour to the drug. The pres-
ence of antibodies on the liposomal surface is expected to result in
increased uptake of immunoliposomes by cells of the mononuclear
phagocytic system (Derksen et al, 1998). However, we observed
that the presence of PEG on the surface of immunoliposomes
attenuates this effect (Scherphof et al, 1997).
For non-targeted, non-long-circulating (conventional) lipo-
somes containing FUdR-dP, increased toxicity compared to free
FUdR has been described (Supersaxo et al, 1988; Van Borssum
Waalkes et al, 1992). This was attributed to the sustained release of
FUdR from Kupffer cells after uptake of the FUdR-dP-liposomes
(Van Borssum Waalkes et al, 1992). Mori et al (1995) showed
however, that a combination of long-circulating capacity and
targeting of the liposomes resulted in improved therapeutic effi-
cacy and less toxicity as compared to conventional liposomes. Our
present approach, in which we combine both liposomal parameters
to target FUdR-dP to colon cancer cells, shows that CC52-
immunoliposomes are able to deliver the active drug to the cancer
cells with high efficiency, by a mechanism probably involving the
selective transfer of the lipophilic prodrug from the immunolipo-
somes to the tumour cell membrane. The obvious advantage of this
approach over the use of an encapsulated drug is that the uptake of
drug proceeds independently of endocytic internalization of the
liposomes as such, a property which may be more generally
applicable for lipophilic (pro)drugs incorporated in targeted
liposomes.
We are currently testing the validity of this formulation with
respect to in vivo anti-tumour activity towards liver metastases of
colon cancer.
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